The treatment and management of COVID-19 patients is evolving rapidly. There is a global effort to discover novel treatments and test existing therapies that are safe and effective. To date, the FDA has only granted a few Emergency Use Authorizations (EUA) for COVID-19 related treatments including: Remdesivir from Gilead Sciences (NASDAQ – GILD), convalescent plasma and gammaCore SapphireTM CV from electroCore, Inc. (NASDAQ – ECOR). More innovation is needed faster. David Shulkin, MD, 9th Secretary of Veterans Affairs, will moderate...

Read More Read More